Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJason GotlibJMJohn MascarenhasRRRaajit K. Rampal

Discussion

Loading...

Member takes

Overview

Multicenter trial evaluates safety and efficacy of INCB160058 in myelofibrosis and other MPNs, suggesting potential improvement in clinical outcomes.

Key Points

  • INCB160058 showed promising safety and tolerability, targeting JAK2V617F in patients with myelofibrosis and other conditions.
  • Key secondary endpoints include pharmacokinetics, clinical efficacy, and reduction of MPN symptom scores at 24 weeks.
  • Phase 1, multicenter trial design focused on assessing adverse events and defining maximum tolerated dose for expansion.
  • This selective inhibition strategy highlights a potential advance in targeted therapy for myeloproliferative neoplasms.

Cite This Study

Gotlib et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d787https://doi.org/10.1182/blood-2025-2051
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms2025
  2. 2A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.2025
  3. 3Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis2025 · 2 citations
  4. 4AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)2025 · 1 citations
  5. 5Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor2025